Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cytomx Thera (CTMX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 809,299
  • Shares Outstanding, K 38,410
  • Annual Sales, $ 15,040 K
  • Annual Income, $ -58,900 K
  • 36-Month Beta 0.47
  • Price/Sales 53.90
  • Price/Cash Flow N/A
  • Price/Book 17.12

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.91 +11.42%
on 11/14/17
21.91 -3.83%
on 11/29/17
+1.32 (+6.68%)
since 11/10/17
3-Month
16.26 +29.58%
on 09/15/17
24.67 -14.59%
on 10/04/17
+4.84 (+29.82%)
since 09/12/17
52-Week
10.40 +102.60%
on 01/03/17
24.67 -14.59%
on 10/04/17
+9.40 (+80.55%)
since 12/12/16

Most Recent Stories

More News
Biotech Stock Roundup: Regeneron Down on Eylea Data, Biogen-Alkermes in MS Deal

While there were not too many updates this week, companies like Regeneron (REGN) and Biogen were in the news related to their pipeline.

CTMX : 21.07 (-0.19%)
REGN : 381.72 (+0.10%)
CPRX : 4.17 (-0.71%)
ALKS : 52.15 (-0.02%)
AMGN : 176.26 (-0.32%)
BIIB : 327.75 (-0.09%)
CytomX Therapeutics Announces FDA Acceptance of Investigational New Drug Application for CTLA-4 Probody Therapeutic

Goal is a safer, more effective version of Yervoy

CTMX : 21.07 (-0.19%)
CytomX Announces Third Quarter 2017 Financial Results and Operational Progress

SOUTH SAN FRANCISCO, CA--(Marketwired - Nov 7, 2017) - CytomX Therapeutics, Inc. (NASDAQ: CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer,...

CTMX : 21.07 (-0.19%)
CytomX Announces Third Quarter 2017 Financial Results and Operational Progress

SOUTH SAN FRANCISCO, CA--(Marketwired - Nov 7, 2017) - CytomX Therapeutics, Inc. (NASDAQ: CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer,...

CTMX : 21.07 (-0.19%)
CytomX to Present at the Jefferies 2017 London Healthcare Conference

CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody(TM) therapeutics for the treatment of cancer, will present at the Jefferies 2017 London Healthcare...

CTMX : 21.07 (-0.19%)
CytomX Therapeutics to Announce Third Quarter 2017 Financial Results

CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody(TM) therapeutics for the treatment of cancer, will announce financial results for the third quarter...

CTMX : 21.07 (-0.19%)
CytomX Therapeutics Appoints Charles S. Fuchs, M.D., MPH to Board of Directors

CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody(TM) therapeutics for the treatment of cancer, today announced the appointment of Charles S. Fuchs,...

CTMX : 21.07 (-0.19%)
CytomX Announces Upcoming Poster Presentations at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference

CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody(TM) therapeutics for the treatment of cancer, today announced that preclinical results will be presented...

CTMX : 21.07 (-0.19%)
Cancer Space Last Week Update: Pipeline Expansion in Focus

Last week, a few companies in the cancer segment entered deals for expanding their portfolio. Another key development was a ruling in favor of a major cancer drug by the U.S. patent office.

CTMX : 21.07 (-0.19%)
LLY : 86.71 (+0.05%)
ECYT : 4.56 (-4.00%)
SGEN : 54.61 (-1.19%)
CLSN : 2.83 (+7.20%)
AMGN : 176.26 (-0.32%)
Today's Research Reports on Stocks to Watch: Amicus Therapeutics and CytomX Therapeutics

NEW YORK, NY / ACCESSWIRE / October 5, 2017 / Amicus Therapeutics and CytomX Therapeutics both hit new highs on Wednesday. CytomX announced a partnership with Amgen to develop an immuno-oncology drug...

FOLD : 12.98 (-1.37%)
CTMX : 21.07 (-0.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered...

See More

Key Turning Points

2nd Resistance Point 21.38
1st Resistance Point 21.23
Last Price 21.07
1st Support Level 20.87
2nd Support Level 20.67

See More

52-Week High 24.67
Last Price 21.07
Fibonacci 61.8% 19.22
Fibonacci 50% 17.53
Fibonacci 38.2% 15.85
52-Week Low 10.40

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.